(182) Health-Related Quality of Life of Indonesian Cancer Patients: Comparison of EORTC QLQ C30 and EQ5D Questionnaires

Saturday, August 27, 2022

8:00 AM – 6:00 PM CEST

Location: Hall C

Publication Number: 856

Presenting Author(s)

Dyah A. Perwitasari, Pharm
– Lecturer/Researcher, Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia, Universitas Ahmad Dahlan, Yogyakarta, Yogyakarta, Indonesia

Co-Author(s)

Fredrick D. Purba
– Faculty of Psychology, Universitas Padjadjaran, Bandung, Indonesia
Susan F. Candradewi
– Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
Bayu Septiantoro
– Pharmacy Departement, Kariyadi Hospital, Semarang, Indonesia

Background: Currently, cancer is still being burden in Indonesia. Among 270 million of Indonesia population, 0.12% and 0.07% of them were the cancer cases and cancer deaths, respectively. Based on the Indonesia National Health Insurance data, cancer had the most absorption cost which is considerably as the catastrophic cost. Cost and effectiveness analysis of the cancer treatment must be developed, due to the new drug availability for cancer treatment and could be considered in the insurance coverage. Health-related quality of life (HR-QoL) is one of the effectiveness outcomes which can be used in the cost effectiveness and cost utility analysis.

Objectives: to compare the HR-QoL domains in European Organization of Research and Treatment of Cancer (EORTC QLQ-C30) and EQ 5D.

Methods: We used cross sectional design with the total number of patients 455, recruited in Kariyadi Hospital, Semarang, Indonesia. All cancer patients who agree to participate in this study were recruited during 6 months in 2019-2020. The inclusion criteria were adult cancer patients who conducted chemotherapy and proceed the inform consent. Cancer patients with many comorbidities were excluded. We used Indonesian version of EORTC QLQ C-30 and EQ 5D for measuring cancer patients quality of life. We described the cancer patients' characteristics and their HR-QoL using descriptive analysis.

Results: Most of the subjects are female (69.4%), the age is between 25-59 yo (86%), advance stage of cancer (54.1%), breast cancer (35.7%). Based on the domains in the EORTC QLQ-C30, the higher function is cognitive (89.43) and the lowest is role function (65.56), the higher score is the better function. The worst symptoms experienced by the patients is weakness, followed by pain, insomnia and appetite loss. The global health score is 68.05. Based on the EQ-5D, the worst domain score with more frequent cancer patients is usual activities (9.2%). In all domains, most cancer patients express no problem and the score of visual analog scale is 72.09, higher than the global health score of EORTCC QLQ C30. The scale of physical and emotional function in EORTC QLQ C30 is higher than the scales in EQ 5D. This pattern is similar to the visual analog scale and global health scale. This could be caused by the the sensitiveness of the specific questionnaire

Conclusions: This study shows that score of similar domains in both questionnaires is different, where ever the score of EORTC QLQ C-30 is higher than the score of EQ 5D. The higher score means the worst situation. In this case, EORTC QLQ C30 is more sensitive than EQ5D.